Zacks: Analysts Expect Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Will Post Quarterly Sales of $2.25 Million

Equities analysts predict that Marinus Pharmaceuticals, Inc. (NASDAQ:MRNSGet Rating) will report sales of $2.25 million for the current quarter, according to Zacks. Five analysts have provided estimates for Marinus Pharmaceuticals’ earnings. The highest sales estimate is $2.63 million and the lowest is $2.00 million. Marinus Pharmaceuticals reported sales of $1.81 million during the same quarter last year, which would suggest a positive year over year growth rate of 24.3%. The firm is scheduled to issue its next earnings results on Monday, January 1st.

According to Zacks, analysts expect that Marinus Pharmaceuticals will report full year sales of $17.59 million for the current year, with estimates ranging from $10.58 million to $23.20 million. For the next financial year, analysts expect that the business will report sales of $53.42 million, with estimates ranging from $16.89 million to $127.00 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research firms that cover Marinus Pharmaceuticals.

Marinus Pharmaceuticals (NASDAQ:MRNSGet Rating) last announced its quarterly earnings results on Monday, March 21st. The biopharmaceutical company reported ($0.77) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.81) by $0.04. Marinus Pharmaceuticals had a negative return on equity of 121.57% and a negative net margin of 643.70%. The business had revenue of $1.52 million during the quarter, compared to analysts’ expectations of $2.64 million. During the same quarter last year, the business posted ($0.55) earnings per share.

A number of brokerages have issued reports on MRNS. SVB Leerink decreased their price target on Marinus Pharmaceuticals from $30.00 to $27.00 and set an “outperform” rating on the stock in a research note on Tuesday, March 22nd. Truist Financial raised their price target on Marinus Pharmaceuticals from $35.00 to $50.00 and gave the stock a “buy” rating in a research note on Tuesday, March 22nd. JMP Securities lifted their price objective on Marinus Pharmaceuticals from $21.00 to $22.00 and gave the company a “market outperform” rating in a research note on Tuesday, March 22nd. Zacks Investment Research raised Marinus Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, February 26th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $38.00 price objective on shares of Marinus Pharmaceuticals in a research note on Tuesday, March 22nd. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat, the company has an average rating of “Buy” and an average target price of $30.17.

Hedge funds and other institutional investors have recently modified their holdings of the company. Morgan Stanley boosted its position in Marinus Pharmaceuticals by 22.7% during the 2nd quarter. Morgan Stanley now owns 84,161 shares of the biopharmaceutical company’s stock valued at $1,509,000 after purchasing an additional 15,593 shares during the period. Invesco Ltd. acquired a new position in Marinus Pharmaceuticals during the 2nd quarter valued at approximately $210,000. SG Americas Securities LLC acquired a new position in Marinus Pharmaceuticals during the 3rd quarter valued at approximately $806,000. Victory Capital Management Inc. boosted its position in Marinus Pharmaceuticals by 7.6% during the 3rd quarter. Victory Capital Management Inc. now owns 102,269 shares of the biopharmaceutical company’s stock valued at $1,164,000 after purchasing an additional 7,190 shares during the period. Finally, Grimes & Company Inc. boosted its position in Marinus Pharmaceuticals by 10.2% during the 3rd quarter. Grimes & Company Inc. now owns 29,128 shares of the biopharmaceutical company’s stock valued at $331,000 after purchasing an additional 2,697 shares during the period. Institutional investors and hedge funds own 85.95% of the company’s stock.

Shares of MRNS traded down $0.43 during trading hours on Monday, reaching $7.37. 132,087 shares of the company traded hands, compared to its average volume of 330,768. The company has a quick ratio of 3.25, a current ratio of 3.25 and a debt-to-equity ratio of 0.83. The stock has a market capitalization of $272.80 million, a PE ratio of -2.74 and a beta of 1.34. Marinus Pharmaceuticals has a fifty-two week low of $7.16 and a fifty-two week high of $19.83. The stock has a fifty day simple moving average of $9.22 and a 200 day simple moving average of $10.59.

About Marinus Pharmaceuticals (Get Rating)

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY, an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.

Further Reading

Get a free copy of the Zacks research report on Marinus Pharmaceuticals (MRNS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Marinus Pharmaceuticals (NASDAQ:MRNS)

Receive News & Ratings for Marinus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marinus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.